Diabetes and cancer (1): Evaluating the temporal relationship between type 2 diabetes and cancer incidence

Diabetologia

Volumn 55, Issue 6, 2012, Pages 1607-1618

  Johnson, J A ^a   Carstensen, B ^b,c   Witte, D ^b   Bowker, S L ^a   Lipscombe, L ^d   Renehan, A G ^e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bias; Cancer.confounding; Diabetes; Epidemiology; Incidence; Review; Temporal; Type 2 diabetes

Indexed keywords

INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; ENDOMETRIUM CANCER; GLYCEMIC CONTROL; HUMAN; KIDNEY CANCER; LIFESTYLE; LIVER CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBESITY; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; MORTALITY; NEOPLASM; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84865414136     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2525-1     Document Type: Review

References (87)

1. Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33:1674-1685
2. Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708
3. Papanikolaou PN, Christidi GD, Ioannidis JP (2006) Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174:635e41
4. Golder S, Loke YK, Bland M (2011) Meta-analyses of adverse effects data derived from randomized controlled trials as compared to observational studies; methodological overview. PLoS Med 8:e1001026
5. Vandenbroucke JP, Psaty BM (2008) Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300:2417-2419
6. PLoS Medicine Editors (2011) Why drug safety should not take a back seat to efficacy. PLoS Med 8:e1001097. doi:10.1371/journal.pmed.1001097
7. Johnson JA, Gale EA (2010) Diabetes, insulin use and cancer risk: are observational studies part of the solution-or part of the problem? Diabetes 59:1129-1131
8. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EAM, Moller H. (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia doi:10.1007/s00125-012-2526-0
9. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103-1123
10. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47:87-95
11. Larsson SC, Mantzoros CS, Wolk S (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856-862 (Pubitemid 47106217)
12. Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679-1686
13. Friberg E, Orsini N, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365-1374 (Pubitemid 46879010)
14. Larsson SC, Wolk A (2011) Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54:1013-1018
15. Larsson SC, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49:2819-2823 (Pubitemid 44730282)
16. Mitri J, Castillo J, Pittas AG (2008) Diabetes and risk of non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care 31:2391-2397
17. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076-2083 (Pubitemid 40897433)
18. El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369-380 (Pubitemid 43343895)
19. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:2056-2062 (Pubitemid 44877026)
20. Hall GC, Roberts CM, Boulis M, Mo J, MacRae KD (2005) Diabetes and the risk of lung cancer. Diabetes Care 28:590-594 (Pubitemid 40315318)
21. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO (2002) Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 13:759-764 (Pubitemid 35204052)
22. Yamagata H, Kiyohara Y, Nakamura S et al (2005) Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care 28:789-794 (Pubitemid 40434474)
23. Noto H, Osame K, Sasazuki T, Noda M (2010) Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 24:345-353
24. Swerdlow AJ, Laing SP, Qiao Z et al (2005) Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 92:2070-2075 (Pubitemid 40897432)
25. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A (1997) Cancer and diabetes-a follow-up study of two populationbased cohorts of diabetic patients. J Intern Med 241:471-475 (Pubitemid 27315827)
26. Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K (2010) Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 27:791-797
27. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797-1800 (Pubitemid 38008903)
28. Tabak AG, Jokela M, Akbaraly TN, Kivimaki M, Witte D (2009) Trajectories of glycemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373:2215-2221
29. Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8:915-928
30. Frasca F, PandiniG SP et al (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288 (Pubitemid 29193789)
31. Vella V, Pandini G, Sciacca L et al (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Met 87:245-254 (Pubitemid 34084698)
32. Pisani P (2008) Hyperinsulinemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114:63-70 (Pubitemid 351998745)
33. Goodwin PJ (2008) Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 26:833-834 (Pubitemid 351398072)
34. van Kruijsdijk RC, van der Wall E, Visseren FL (2009) Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 18:2569-2578
35. Gerstein HC (2010) Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA 303:446-447
36. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194-202 (Pubitemid 40095870)
37. Park SM, Lim MK, Shin SA, Yun YH (2006) Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 24:5017-5024
38. Stocks T, Rapp K, Bjørge T et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6:e1000201
39. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829-841
40. Pollak M (2009) Do cancer cells care if their host is hungry? Cell Metab 9:401-403
41. Tannock IF, Kopelyan I (1986) Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res 46:3105-3110 (Pubitemid 16074335)
42. Johnson JA, Bowker SL (2011) Intensive glycemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54:25-31
43. Johnson JA, Pollak M (2010) Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 53:2086-2088
44. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578 (Pubitemid 351232031)
45. Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H (2006) Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 84:427-433 (Pubitemid 44699156)
46. Wei M, Gaskill SP, Haffner SM, Stern MP (1997) Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans-a 7-year prospective study. Obes Res 5:16-23 (Pubitemid 127702765)
47. Pischon T, Lahmann PH, Boeing H et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98:920-931 (Pubitemid 44018922)
48. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington DC
49. Barclay AW, Petocz P, McMillan-Price J et al (2008) Glycemic index, glycemic load, and chronic disease risk-a metaanalysis of observational studies. Am J Clin Nutr 87:627-637 (Pubitemid 351364544)
50. Davidson LE, Hudson R, Kilpatrick K et al (2009) Effects of exercise modality on insulin resistance and functional limitations in older adults. Arch Intern Med 169:122-131
51. Sasco AJ, Secretan MB, Straif K (2004) Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer 45(Suppl 2):S3-S9 (Pubitemid 39488165)
52. Clark AM, Raine K, Pahpael D (2004) The American Cancer Society, American Diabetes Association and American Heart Association Joint Statement on preventing cancer, cardiovascular disease and diabetes: where are the social determinants? Diabetes Care 27:3024 (Pubitemid 39565089)
53. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-647
54. Meza R, Jeon J, Renehan AG, Luebeck EG (2010) Colorectal cancer incidence trends in the United States and United Kingdom: evidence of right-to left-sided biological gradients with implications for screening. Cancer Res 70:5419-5429
55. Renehan AG (2009) Bariatric surgery, weight reduction and cancer prevention. Lancet Oncol 10:640-641
56. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) San Antonio metabolism study. Diabetologia 47:31-39
57. Johnson JA, Bowker SL, Richardson K, Marra CA (2011) Timevarying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 54:2263-2271
58. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492-499
59. Rewers M (2008) Why do people with diabetes die too soon? Diabetes Care 31:830-831
60. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305 (Pubitemid 40813563)
61. Currie CJ, Poole CD, Gale EAM (2009) The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
62. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625
63. Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044-1050 (Pubitemid 39345873)
64. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258 (Pubitemid 44106500)
65. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
66. Mannucci E, Monami M, Balzi D et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33:1997-2003
67. Govindarajan R, Ratnasinghe L, Simmons DL et al (2007) Thiazolidinediones and risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476-1481 (Pubitemid 46733074)
68. Lewis JD, Ferrara A, Peng T et al (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916-922
69. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M (2010) Metformin blocks the stimulative effect of a highenergy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17:351-360
70. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273 (Pubitemid 44799743)
71. Psaty BM, Koepsell TD, Lin D et al (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749-754 (Pubitemid 29266647)
72. Ray W (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915-920 (Pubitemid 37323253)
73. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
74. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765
75. Erratum 52:2469
76. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150-156
77. Garg SK, Hirsch IB, Skyler JS (2009) Insulin glargine and cancer-an unsubstantiated allegation. Diabetes Technol Ther 29:473-476
78. Duncan BB, Schmidt MI (2009) Metformin, cancer, alphabet soup and the role of epidemiology in etiologic research. Diabetes Care 32:1748-1750
79. Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511-513
80. Gale EA (2009) Insulin glargine and cancer: another side to the story? Lancet 374:521
81. Prospective Diabetes Group UK (1998) Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes. UKPDS 34. Lancet 352:854-865
82. DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: A systematic review and metaanalysis. Cancer Prev Res 3:1451-1461
83. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012 (Pubitemid 29254858)
84. Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M (2009) No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 52:2507-2512
85. Home PD, Lagarenne P (2009) Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 52:2499-2506
86. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G, ADOPT Study Group; RECORD Study Steering Committee (2010) Experience of malignancies with oral glucoselowering drugs in the randomized controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes) clinical trials. Diabetologia 53:1838-1845
87. Johnson JA, Yasui Y (2010) Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations. Diabetologia 53:1823-1826